Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes - PubMed (original) (raw)

Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes

Wai-Ping Woo et al. J Virol. 2006 Apr.

Abstract

Although hepatitis B surface antigen (HBsAg) per se is highly immunogenic, its use as a vector for the delivery of foreign cytotoxic T-lymphocyte (CTL) epitopes has met with little success because of constraints on HBsAg stability and secretion imposed by the insertion of foreign sequence into critical hydrophobic/amphipathic regions. Using a strategy entailing deletion of DNA encoding HBsAg-specific CTL epitopes and replacement with DNA encoding foreign CTL epitopes, we have derived chimeric HBsAg DNA immunogens which elicited effector and memory CTL responses in vitro, and pathogen- and tumor-protective responses in vivo, when the chimeric HBsAg DNAs were used to immunize mice. We further show that HBsAg DNA recombinant for both respiratory syncytial virus and human papillomavirus CTL epitopes elicited simultaneous responses to both pathogens. These data demonstrate the efficacy of HBsAg DNA as a vector for the delivery of disease-relevant protective CTL responses. They also suggest the applicability of the approach of deriving chimeric HBsAg DNA immunogens simultaneously encoding protective CTL epitopes for multiple diseases. The DNAs we tested formed chimeric HBsAg virus-like particles (VLPs). Thus, our results have implications for the development of vaccination strategies using either chimeric HBsAg DNA or VLP vaccines. HBsAg is the globally administered vaccine for hepatitis B virus infection, inviting its usage as a vector for the delivery of immunogens from other diseases.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Immunization with chimeric HBsAg DNA encoding an RSV CTL epitope at ΔIPQ and/or ΔGLS elicits RSV-directed CTL responses. (a to e) Epitope-specific IFN-γ-secreting T-cell response following immunization of BALB/c mice (three per group) immunized twice i.d. (a) with pM29ΔIPQ, (b) with pM215ΔIPQ, or (c) with pM215ΔGLS. Control mice were immunized (d) once with M215 peptide plus adjuvant s.c. or (e) twice with wild-type HBsAg DNA (pHBsAg) i.d. IFN-γ-secreting cells were quantified by ELISPOT assay in splenocytes harvested at 14 days (DNA immunizations) or 10 days (peptide immunizations) after immunization and incubated for 15 to 18 h with specific peptide (M215 or IPQ) or without peptide, as shown. Bars represent means ± standard deviations of three replicates. (f to j) Epitope-specific CTL memory responses. Groups of mice (three per group) were immunized as described above. Percent cytotoxicity of splenocytes restimulated with RSV-specific M215 or HBsAg-specific IPQ peptide was measured in a 51Cr release assay using target cells pulsed with M215 or IPQ peptide or without peptide as shown. Data points represent means of three replicates ± standard deviations. (Note that in some cases standard deviation bars, though plotted, are too small to appear.) (k and l) BALB/c mice (three per group) were immunized three times i.d. with chimeric HBsAg DNAs encoding the M215 CTL epitope inserted either at one location (pM215ΔIPQ.HWI or pM215ΔGLS.HWI) or at two locations (pM215ΔIPQ.ΔGLS.HWI). Control mice were immunized with pHBsAg wild-type DNA. (k) IFN-γ-secreting cells were quantified by ELISPOT assay using ex vivo splenocytes incubated with or without M215 peptide. (l) Percent cytotoxicity of splenocytes restimulated for 6 days with M215 peptide was quantified in a 51Cr release assay using target cells pulsed with M215 peptide or without peptide as shown.

FIG. 2.

FIG. 2.

Chimeric HBsAg DNA encoding RSV M2 CTL epitope elicits protection against RSV infection and disease. BALB/c mice (five per group) were (ii) immunized twice i.d. with pM215ΔGLS DNA or (i and iii) unimmunized and (i and ii) challenged 2 weeks later with 8 × 105 PFU RSV or (iii) left unchallenged. Four days later, mice lungs were processed for (a) hematoxylin-eosin staining and (b) immunostaining with goat anti-RSV antibody.

FIG. 3.

FIG. 3.

Chimeric HBsAg DNA encoding a CTL epitope of HPV16 E7 elicits E7-directed CTL responses and protects against challenge with E7-expressing tumor. (a to c) A2.1Kb mice (three per group) were immunized twice i.d. with pRAHΔIPQ DNA or with pHBsAgWT DNA or once s.c. with RAH peptide plus adjuvant. IFN-γ-secreting splenocytes harvested at 14 days (DNA immunizations) or 10 days (peptide immunizations) were quantified by ELISPOT assay with or without specific peptide (RAH) as shown. Bars are means ± standard errors of three replicates. (d to f) CTL responses following immunization with pRAHΔIPQ DNA. Mice (three per group) were immunized as described above. Percent cytotoxicity of splenocytes restimulated with RAH peptide was measured in a 51Cr release assay using EL4.A2 target cells pulsed with or without RAH peptide. Data points are means ± standard deviations of three replicates (although plotted, standard deviation bars are too small to appear). (g and h) Growth of E7-expressing tumor in immunized mice and controls. Mice immunized with pRAHΔIPQ DNA, with pHBsAg wild-type DNA, or with RAH peptide plus adjuvant and unimmunized mice were challenged with 2 × 105 E7-expressing TC-1 tumor cells on day 14 postimmunization. Results are expressed as tumor-free mice (%) at the indicated time points. Groups of tumor-challenged mice were compared by use of the log rank statistic.

FIG. 4.

FIG. 4.

Immunization with chimeric HBsAg DNA encoding two protective CTL epitopes from distinct pathogens elicits CTL responses to both epitopes. (a and b) Epitope-specific IFN-γ-secreting response of ex vivo splenocytes following two i.d. immunizations of mice (BALB/c × A2.1Kb; three per group) with chimeric HBsAg DNA encoding both M215 and RAH epitopes (pM215ΔIPQ.RAHΔGLS.HWI), the M215 epitope alone (pM215ΔIPQ), or the RAH epitope alone (pRAHΔGLS). IFN-γ-secreting cells were quantified by ELISPOT assay using splenocytes incubated for 15 to 18 h with or without specific peptide M215 or RAH as shown. Histogram bars represent means ± standard deviations of three replicates. (c and d) Percent cytotoxicity of splenocytes restimulated with RAH peptide or with M215 peptide measured in a 51Cr release assay using P815 or EL4.A2 target cells pulsed with M215 peptide or RAH peptide, respectively, or without peptide, as shown. Data points represent means ± standard deviations of three replicates (standard deviation bars, although plotted, are too small to appear in some cases). (e) Growth of E7-expressing tumor in mice immunized with pM215ΔIPQ.RAHΔGLS.HWI DNA, with pRAHΔ IPQ DNA, or with control DNA as indicated. Mice (five per group) were challenged with 2 × 105 E7-expressing TC-1 tumor cells on day 14 postimmunization. Results are expressed as tumor-free mice (%) at the indicated time points. Differences between means (*, **, ***) were calculated using Student's t test. Differences between survival curves (****) were calculated using the log rank statistic.

FIG. 5.

FIG. 5.

Chimeric HBsAgs containing foreign CTL epitopes package HDAg-L for secretion. Culture fluid from HuH-7 cells cotransfected with plasmids encoding chimeric or wild-type HBsAg proteins, and a plasmid encoding HDAg-L, was pelleted through sucrose cushions and resuspended in sample buffer, and supernatants (a) and cell pellets (b) were analyzed by immunoblotting using a human serum antibody specific for HDAg-L. Lanes: 1, pM29ΔIPQ; 2, pM215ΔIPQ; 3, pM215ΔGLS; 4, wild-type pHBsAg; 5, wild-type pHBsAg without pHDAg-L; 6, pHDAg-L without pHBsAg; 7, neither pHDAg-L nor pHBsAg.

Similar articles

Cited by

References

    1. Berger, J., J. Hauber, R. Hauber, R. Geiger, and B. R. Cullen. 1988. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 66:1-10. - PubMed
    1. Bryder, K., H. Sbai, H. V. Nielsen, S. Corbet, C. Nielsen, R. G. Whalen, and A. Fomsgaard. 1999. Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg. DNA Cell Biol. 18:219-225. - PubMed
    1. Chang, F. L., P. J. Chen, S. J. Tu, C. J. Wang, and D. S. Chen. 1991. The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proc. Natl. Acad. Sci. USA 88:8490-8494. - PMC - PubMed
    1. Chargelegue, D., O. E. Obeid, S. C. Hsu, M. D. Shaw, A. N. Denbury, G. Taylor, and M. W. Steward. 1998. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo. J. Virol. 72:2040-2046. - PMC - PubMed
    1. Chengalvala, M. V., R. A. Bhat, B. M. Bhat, S. K. Vernon, and M. D. Lubeck. 1999. Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid. Vaccine 17:1035-1041. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources